How many insider trades does FilingIQ track for COGT?

FilingIQ tracks 178 Form 4 insider transactions for COGT (Cogent Biosciences, Inc.), covering filings from Aug 1, 2016 onwards. 4 of those were filed in the last 90 days.

Are COGT insiders net buyers or net sellers?

Across the full Form 4 history for COGT, 53 transactions (30%) were open-market purchases and 39 (22%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does COGT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is COGT in?

Cogent Biosciences, Inc. (COGT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.92B.

COGT insider trading

NasdaqGS Healthcare

Cogent Biosciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

178

Last 90 days

Buys / sells

30% / 22%

Market cap

$5.92B

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Company website: www.cogentbio.com

COGT insider activity at a glance

FilingIQ has scored 178 insider transactions for COGT since Aug 1, 2016. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 53 open-market purchases and 39 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on COGT insider trades is 52.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live COGT trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding COGT

VR Adviser, LLC

$60.25M · 9.3% of AUM

Frazier Life Sciences Management, L.P.

$24.38M · 1.5% of AUM

Exome Asset Management LLC

$3.83M · 2.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for COGT?: FilingIQ tracks 178 Form 4 insider transactions for COGT (Cogent Biosciences, Inc.), covering filings from Aug 1, 2016 onwards. 4 of those were filed in the last 90 days.
Are COGT insiders net buyers or net sellers?: Across the full Form 4 history for COGT, 53 transactions (30%) were open-market purchases and 39 (22%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does COGT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is COGT in?: Cogent Biosciences, Inc. (COGT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.92B.

Methodology & sources

Every COGT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.